THE AMERICAN ASSOCIATION of
AACE Annual Scientific

CLINICAL ENDOCRINOLOGISTS
& Clinical Congress

Congress Program DISCLOSURE INFORMATION

WEDNESDAY, May 25

6:30 am – 6:30 pm

Registration

12:30 pm – 6:30 pm

CME Station Hours

8:00 am – 12:00 pm

Pre Congress Session I

 

W11: Diabetes Technology 2016
Chair: George Grunberger, MD

  • Update on Insulin Pump Therapy and Continuous Glucose Monitoring
    Bruce W. Bode, MD

Room: Suwannee 16/17
CME Code: 5223

 

W21: Inpatient Endocrinology Part 1: Diabetes and Nutrition
Chair: Etie S. Moghissi, MD; S. Sethu Reddy, MD

Room: Suwannee 11/12
CME Code: 7518

 

W31: Cardiovascular Medicine for the Endocrinologist
Chair: Chris K. Guerin, MD

Room: Suwannee 18/19
CME Code: 7631

 

W41: Comprehensive Approach to Clinical Thyroidology
Chair: Mark Lupo, MD

Room: Suwanee 20/21
CME Code: 6256

1:00 pm – 5:00 pm

W12: Inpatient Endocrinology Part 2: What an Endocrinologist Needs to Know About Surgery and What a Surgeon Needs to Know About Endocrinology
Chair: Mira Milas, MD;& Jeffrey Garber, MD
Thyroid and Parathyroid Session

  • Case-based Panel Discussion

Pituitary and Adrenal Session

  • Case-based Panel Discussion

 

W22: The Practice of Obesity Medicine in 2016
Chair: J. Michael Gonzalez-Campoy, MD, PhD

 

W32: Bone Disease in 2016: Beyond the Basics
Co-Chairs: Daniel L. Hurley, MD; Rachel Pessah-Pollack, MD

 

W42: AACE – ABIM Maintenance of Certification and Mini - Board Review Course
Chair: Pauline M. Camacho, MD
Speakers: Pauline Camacho, MD; Elise Brett, M; Hossein Gharib, MD; Dace Trence, MD

  • Endocrinology Update 2015
  • Endocrinology Update 2016

5:30 pm – 7:45 pm

WSS1: Hypoparathyroidism: New Treatment Concepts & Guidelines

5:30 pm – 7:45 pm

WSS2: Concentrated Insulins: Clinical Applications and Use in Practice Settings

THURSDAY, MAY 26

5:15 am – 7:30 am

TSS1: LDL-C Reduction in the Patient with Diabetes: How Low Should We Go and How Should We Get There?
Room: Panzacola H 1/2
CME Code: 1575

6:30 am – 6:30 pm

Registration

7:00 am – 6:00 pm

CME Station Hours

9:45 am -2:15 pm

Exhibit Hall Hours

8:00 am – 8:30 am

General Session Announcements

8:30 am – 9:15 am

TGS1: Diabetes and the Microbiome
Moderator: George Grunberger, MD
Speaker: Robert E. Ratner, MD

Room: Panzacola F/G
CME Code: 5331

9:15 am – 10:00 am

TGS2: Metabolomics for the Clinician: Implications for the Treatment of Metabolic Disease
Moderator: Derek LeRoith, MD
Speaker: Christopher B. Newgard, PhD

Room: Panzacola F/G
CME Code: 8024

10:00 am – 11:00 am

Young Investigator Poster Session in Exhibit Hall

10:15 am – 11:00 am

Product Theaters in the Exhibit Hall

11:15 am – 12:00 pm

TGS3: Co-Evolution of Scientific Disciplines and Therapies for Disorders of Lipid Metabolism
Moderator: Jonathan D. Leffert, MD
Speaker: Jay D. Horton, MD

Room: Panzacola F/G
CME Code: 2893

12:00 pm – 1:00 pm

Boxed Lunch in Exhibit Hall

12:00 pm – 12:45 pm

Young Investigator ePoster Oral Presentations

12:30 pm – 2:15 pm

Women of Endocrinology Luncheon
Lessons in Leadership: My Path to Presidency (Non-CME)

Moderator: Etie S. Moghissi, MD
Speaker: Pauline M. Camacho, MD

1:00 pm – 1:45 pm

Product Theater in the Exhibit Hall

1:15pm – 2:00 pm

Product Theaters in the Exhibit Hall

2:15 pm – 3:15 pm

MEET-THE-EXPERTS SESSION I

 

T11: The D-Lightful Vitamin D for Health: Truths and Myths
Moderator: Timothy S. Bailey, MD
Speaker: Michael D. Holick, MD

Room: Suwannee 16/17
CME Code: 8253

 

T21: How to Initiate Treatment for Type 2 Diabetes Mellitus: One agent at a Time Versus Combination Therapy
Moderator: Daniel Einhorn, MD
Speakers: Richard E. Pratley, MD vs. Alan J. Garber, MD
Room: Suwannee 11/12
CME Code: 7548

 

T31: Mild Hypercortisolism Due to Adrenal Adenoma – Is It Really “Subclinical?”
Moderator: Janet B. McGill, MD
Speaker: Alice C. Levine, MD

Room: Suwannee 13/14
CME Code: 4915

 

T41: How Low Should You Go: Lipid Management in the PCSK9 Era
Moderator: Richard A. Haas, MD
Speaker: Robert H. Eckel, MD

Room: St. John's 24/25
CME Code: 1886

 

T51: Endocrine Hypertension in 2016: Making the Diagnosis
Moderator: William D. Zigrang, MD
Speaker: William F. Young Jr., MD

Room: St. John's 28/29
CME Code: 1354

 

T61: Pediatric Endocrinology: Optimizing Growth
Moderator: Jay Cohen, MD
Speaker: Robert Rapaport, MD

Handout:1
Handout:2

Room: Suwannee 20/21
CME Code: 3145

 

T71: Practical Strategies for Management of the Pseudo-Endocrine Patient
Moderator: Farhad Zangeneh, MD
Speaker: Michael McDermott, MD

Room: Suwannee 18/19
CME Code: 7336

3:15 pm – 3:30 pm Coffee Break
3:30 pm – 4:30 pm MEET-THE-EXPERTS SESSION II
 

T12: Options for Treatment of Hypogonadism in Men Desiring Fertility Preservation

Handout

Moderator: M. Kathleen Figaro, MD
Speaker: Natan Bar-Chama, MD

Room: Suwannee 15
CME Code: 9554

 

T22: Point/Counterpoint: Radioactive Iodine in Papillary Thyroid Cancer: To Use or Not to Use…That Is the Question
Moderator: Jonathan Insel, MD
Speakers: Kenneth Ain, MD vs. Ian Hay, MD

Room: Suwannee 16/17
CME Code: 1959

 

T32: Is Insulin Therapy Inevitable in the Management of Diabetes?
Moderator: Vivian Fonseca, MD
Speaker: Robert E. Ratner, MD

Room: Suwannee 20/21
CME Code: 7264

 

T42: Mild Hypercortisolism Due to Adrenal Adenoma – Is It Really “Subclinical?”
Moderator: Janet B. McGill, MD
Speaker: Alice C. Levine, MD

Room: Suwannee 13/14
CME Code: 5304

 

T52: How Low Should You Go: Lipid Management in the PCSK9 Era
Moderator: Richard A. Haas, MD
Speaker: Robert H. Eckel, MD

Room: St. John's 24/25
CME Code: 9533

 

T62: Endocrine Hypertension in 2016: Making the Diagnosis
Moderator: Farhad Zanganeh, MD
Speaker: William F. Young Jr., MD

Room: St. John's 28/29
CME Code: 2042

 

T72: Practical Strategies for Management of the Pseudo-Endocrine Patient
Moderator: William D. Zigrang, MD
Speaker: Michael McDermott, MD

Room: Suwannee 18/19
CME Code: 4068

4:30 pm – 4:45 pm Break
4:45 pm – 5:45 pm MEET-THE-EXPERTS SESSION III
 

T13: The D-Lightful Vitamin D for Health: Truths and Myths
Moderator: Timothy S. Bailey, MD
Speaker: Michael F. Holick, MD

Room: St. John's 24/25
CME Code: 3847

 

T23: How to Initiate Treatment for Type 2 Diabetes Mellitus: One agent at a Time versus Combination Therapy
Moderator: Daniel Einhorn, MD
Speakers: Richard E. Pratley, MD vs. Alan J. Garber, MD

Room: Suwannee 11/12
CME Code: 8878

 

T33: Pediatric Endocrinology: Optimizing Growth
Moderator: Jay Cohen, MD
Speaker: Robert Rapaport, MD

Room: Suwannee 18/19
CME Code: 8156

 

T43: Options for Treatment of Hypogonadism in Men Desiring Fertility Preservation

Handout

Moderator:M. Kathleen Figaro, MD
Speaker: Natan Bar-Chama, MD

Room: Suwannee 15
CME Code: 4926

 

T53: Point/Counterpoint: Radioactive Iodine in Papillary Thyroid Cancer: To Use or Not to Use…That is the Question
Moderator: Jonathan Insel, MD
Speakers: Kenneth Ain, MD vs. Ian Hay, MD

Room: Suwannee 16/17
CME Code: 9985

 

T63: Is Insulin Therapy Inevitable in Management of Diabetes?
Moderator: George Grunberger, MD
Speaker: Robert E. Ratner, MD

Room: Suwannee 20/21
CME Code: 7406

 

T73: History of Diabetes Mellitus: 1500 B.C. to Present
Moderator: Chris K. Guerin, MD
Speaker: Philip Levy, MD

Room: Suwannee 13/14
CME Code: 1465

6:00 pm – 7:00 pm Domestic & International Chapter Receptions
7:15 pm – 9:30 pm

TSS3: Balancing the Evidence: Considering the Clinical Impact of Newer Antihyperglycemic Agents for the Treatment of Type 2 Diabetes

Room: Panzacola H 3/4
CME Code: 1284

 

TSS4: Patient Centered Care of the Patient with Obesity

Room: Panzacola H 1/2
CME Code: 1304

FRIDAY, MAY 27

5:15am – 7:30 am

FSS1: Keeping Pace with CGM Technology: The Path to Successful Implementation
Room: Panzacola H 1/2
CME Code: 3374

7:30am – 6:30 pm

Registration

7:30am – 6:30 pm

CME Station Hours

9:45am – 2:15 pm

Exhibit Hall Hours

8:00am – 8:20 am

General Session Announcements

8:20am – 9:05 am

FGS1:Pheochromocytoma: Then and Now - A 90-Year Journey
Moderator: Daniel L.Hurley, MD
Speaker: William F.Young Jr., MD

Room: Panzacola F/G
CME Code: 7835

9:15am – 12:00 pm

IN-DEPTH SYMPOSIA SESSION I
MOC Points will beavailable for select In-Depth Symposia

 

F11: Thryoid Cancer Update
Chair: Hossein Gharib, MD
Supported by the Hossein Gharib, MD Educational Fund

  • Radioactive Iodine Treatment inThyroid Cancer
    Gregory A. Wiseman, MD

Room: Panzacola H 3/4
CME Code: 1412

 

F21: Endocrine Disorders during Pregnancy
Chair: Felice A.Caldarella, MD

Room: Suwannee 13/14
CME Code: 8929

 

F31: AACE Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity
Chair: W. Timothy Garvey, MD

  • Benefits of Weight Loss Treatment
    Ania Jastreboff, MD

Room: St. John's 24/25
CME Code: 7583

 

F41: Diabetes Update 2016
Chair: Robert R. Henry, MD

 

F51: Practical Clinical Guide to Endocrine Diseases for Nurse Practitioners/ Physician Assistants
Chairs: W. Reid Litchfield, MD; Sondra O’ Callaghan, PA

 

F61: Novel Developments in Diabetes Technology (Non-CME)
Moderators: Timothy Bailey, MD; Alan Garber, MD; R. Mack Harrell, MD

Room: Suwannee 18/19

12:00pm – 2:15 pm

Exhibit Hall Break

12:00pm – 1:00 pm

Boxed Lunch in Exhibit Hall

12:00pm – 12:45 pm

ePoster Oral Presentations

12:30pm – 2:15 pm

FIT Luncheon

1:00pm – 1:45 pm

Product Theater in the Exhibit Hall

1:15pm– 2:00 pm

Product Theaters in the Exhibit Hall

2:15pm – 5:00 pm

IN-DEPTH SYMPOSIASESSION II
MOC Points will beavailable for select In-Depth Symposia

 

F12: A Tributeto Saul Hertz: 75th Anniversary of the Use of Radioactive Iodine
Chair: Jeffrey R.Garber, MD; Lewis E. Braverman, MD

  • The Sodium/Iodide Symporter (NIS): From Patient to Molecule and Back
    Nancy Carrasco, MD
  • Targeted Approaches for Enhancing RAI Avidity in Thyroid Cancer
    Alan Ho, MD

Room: Suwannee 15
CME Code: 9758

 

F22: TransgenderMedicine: What an Endocrinologist Should Know
Chair: Vin Tangpricha, MD

Room: Suwannee 11/12
CME Code: 9137

 

F32: Endocrinology and Aging, or, “The Taper”
Chair: Peter A. Singer, MD

Room: Panzacola H 3/4
CME Code: 2266

 

F42: Neuroendocrine Tumor (NET) Syndromes
Chair: Aaron I. Vinik, MD

Room: Suwannee 16/17
CME Code: 1040

 

F52: 8th AACE/SMNE Joint Session: Reflections and Future Directions in Endocrinology
(presented in Spanish)
Co-Chairs: Myriam Allende-Vigo, MD & Miguel A.Madero, MD

Room: Suwannee 18/19
CME Code: 9910

 

F62: The Future of Endocrinology Reimbursement
Co-Chairs: Katherine Roberts, MD; Howard Lando, MD

  • Creating a New Business Model For Endocrinology: The ACO and the Endocrinologist
    William Biggs, MD
  • Informatics 2016: How Do We Get from Meaningful Use to Precision Medicine?
    Douglas Fridsma, MD

Room: Suwannee 20/21
CME Code: 1073

5:00pm – 6:15 pm

Poster Session in Exhibit Hall

5:00pm – 6:30 pm

Wine & Cheese Reception in Exhibit Hall

6:15pm – 7:00 pm

Product Theaters in the Exhibit Hall

7:00pm – 9:15 pm

FSS3: Basal Insulin 4.0: Updating Your Clinical Practice with Ultralong-acting Insulins

Room: Panzacola H 1/2
CME Code: 6224

7:00pm – 9:15 pm

FSS4: Updates in Cardiovascular Risk Reduction in Type 2 Diabetes: New Insights and Outcomes in Treatment Options

Room: Panzacola H 3/4
CME Code: 1809

SATURDAY, MAY 28

7:30am – 5:00 pm

Registration

7:00am – 6:00 pm

CME Station Hours

9:45am -2:15 pm

Exhibit Hall Hours

8:00am – 8:15 am

Award Presentations

8:15am – 9:00 am

SGS1: The Role of Molecular Markers in Thyroid Nodule Management: Then and Now
Moderator: Hossein Gharib, MD
Speaker:Yuri Nikiforov, MD
Room: Panzacola F/G
CME Code: 3245

9:00am – 9:15 am

Award Presentations

9:15am – 10:00 am

SGS2: The Obesity Epidemic, A Public Health Emergency?
Moderator:Yank Coble, MD
Speaker: Regina Benjamin, MD
Room: Panzacola F/G
CME Code: 3103

 

SGS3: Select Abstract Oral Presentations I
Moderator: S. Sethu Reddy, MD

THE PREVALENCE OF FASTING-EVOKED EN-ROUTE HYPOGLYCEMIA IN DIABETES (FEEHD) IN CLINICAL PRACTICE: A PILOTSURVEY
Saleh Aldasouqi, MD

CONTEMPLATING AN ADDITIONAL ORAL AGENTFOR YOUR PATIENT WITH TYPE 2 DIABETES? CONSIDER POSSIBLE INTERACTION BETWEENQUALITY OF YOUR CONVERSATION WITH PATIENT’S ATTEMPTS AT BARGAINING ANDSELF-REPORTED OUTCOMES - LESSONS FROM THE INTRODIA™ STUDY
Leo Seman, MD

A RANDOMIZED CONTROL TRIAL ON REDUCTIONOF HEMOGLOBIN A1C USING CELL PHONES, COMMUNITY HEALTH WORKERS OR COMBINATIONOF BOTH IN A DISTRICT OF COLUMBIA AFRICAN AMERICAN POPULATION
Nesreen Hagahmed, MBBS

Room: Panzacola H 1/2
CME Code: 6849

 

SGS4: Select Abstract Oral Presentations II
Moderator: David Lieb, MD

SYSTEMATIC REVIEW OF THE POSITIVE PREDICTIVE VALUE OF RAS MUTATIONSIN CYTOLOGICALLY INDETERMINATE THYROID NODULES
Mark Lupo, MD

RADIO FREQUENCY ABLATION: AN INNOVATIVE TREATMENT FORADRENAL NEOPLASMS
Lima Lawrence, MD

USE OF A DIGITAL HEALTH OFFERING TO OPTIMIZE STATIN TREATMENT IN PATIENTS WITH TYPE 2 DIABETES
Juan Frias, MD, FACE

Room: Panzacola H 3/4
CME Code: 8071

10:00am – 11:00 am

Late Breaking Poster Session in Exhibit Hall

10:15am – 11:00 am

Product Theaters in the Exhibit Hall

11:00am – 11:15 am

Award Presentations

11:15am – 12:00 pm

SGS5: Osteoporosis Drugs: Then and Now
Moderator: Pauline M. Camacho, MD
Speaker: Michael R. McClung, MD

Room: Panzacola F/G
CME Code: 4744

11:15am – 12:15 pm

SGS6: Late Breaking Oral Presentations (Non-CME)
Moderators: S. Sethu Reddy, MD; David C. Lieb, MD

Room: Panzacola H 1/2

12:15pm – 2:00 pm

AACE Annual Business Meeting Luncheon

2:15pm – 3:15 pm

MEET-THE-EXPERTS SESSION I

 

S11: Treatment of Severe Pediatric Obesity
Moderator: Sripriya Raman, MD
Speaker: Ilene Fennoy, MD

Room: Suwannee 20/21
CME Code: 1741

 

S21: Update on the Evaluation and Treatment of Paget’s Disease
Moderator: Ved V.Gossain, MD
Speaker: Henry G. Bone III, MD

Room: St. John's 28/29
CME Code: 1429

 

S31: Hormonal Treatment of Menopausal Women: What Are the Data Telling Us (and Not Telling Us?)
Moderator: Kathleen Wyne, MD
Speaker: S. Mitchell Harman, MD

Room: Suwannee 16/17
CME Code: 3734

 

S41: Diagnosis and Management of Anabolic Steroid Abuse

Slides PDF
Moderator: Sri Prakash Mokshagundam, MD
Speaker: Darius A. Paduch, MD

Room: Suwannee 15
CME Code: 8320

 

S51: Improving the Long-Term Management of Benign Thyroid Nodules
Moderator: Sandra L.Weber, MD
Speaker: Stephanie Lee, MD

Room: St John's 24/25
CME Code: 6429

 

S61: Active Surveillance Versus Surgery in Low-Risk Thyroid Cancer
Moderator: Gary A.Trager,MD
Speaker: Juan P. Brito,MD

Room: Suwannee 13/14
CME Code: 1901

 

S71: Hyponatremia: Clinical Conundrums in Diagnosis and Treatment
Moderator: David S.H.Bell, MD
Speaker: Joseph G.Verbalis, MD

Room: Suwannee 11/12
CME Code: 2819

 

S81: Approach to the Transgender Adolescent: The Evaluation
Moderator: Vin Tangpricha, MD
Speaker: Stephen M. Rosenthal, MD

Room: Suwannee 18/19
CME Code: 3838

3:15pm– 3:30pm

Coffee Break

3:30pm – 4:30 pm

MEET-THE-EXPERTS SESSION II

 

S12: Challenging Pituitary Cases
Moderator: Anne L. Leddy, MD
Speaker: Eliza B. Geer,MD

Room: Suwannee 16/17
CME Code: 4222

 

S22: Emerging Therapies for Treatment of Hypoparathyroidism
Moderator: Dace Trence,MD
Speaker: Bart L.Clarke, MD

Room: Suwanee 20/21
CME Code: 4887

 

S32: Approach to the Transgender Adolescent: A Case Study of the Jennings Family
Moderator: Stephen M. Rosenthal, MD; Vin Tangpricha,MD
Case Study: The Jennings Family (“I am Jazz”)
Room: Suwannee 18/19
CME Code: 4907

 

S42: Active Surveillance Versus Surgery in Low-Risk Thyroid Cancer
Moderator: Gary A.Trager, MD
Speaker: Juan P. Brito,MD

Room: Suwannee 13/14
CME Code: 9250

 

S52: Diagnosis and Management of Anabolic Steroid Abuse

Slides PDF
Moderator: Sri Prakash Mokshagundam,MD
Speaker: Darius Paduch, MD

Room: Suwannee 15
CME Code: 7699

 

S62: Improving the Long-Term Management of Benign Thyroid Nodules
Moderator: Elise Brett, MD
Speaker: Stephanie Lee, MD

Room: St. John's 24/25
CME Code: 3718

 

S72: Osteoporosis Drug Holidays: Why, When and What's After
Moderator: Victor L. Roberts, MD
Speaker: Paul D. Miller, MD

Room: St. John's 28/29
CME Code: 4714

 

S82: Hyponatremia: Clinical Conundrums in Diagnosis and Treatment
Moderator: David S. H. Bell, MD
Speaker: Joseph G. Verbalis, MD

Room: Suwannee 11/12
CME Code: 5867

4:30pm – 4:45 pm

Break

4:45pm – 5:45 pm

MEET-THE-EXPERTS SESSION III

 

S13: Treatmentof Severe Pediatric Obesity
Moderator: Sripriya Raman, MD
Speaker: Ilene Fennoy,MD

Room: Suwannee 15
CME Code: 9405

 

S23: Hormonal Treatment of Menopausal Women: What Are the Data Telling Us (and Not Telling Us?)
Moderator: Rhoda H.Cobin, MD
Speaker: S. Mitchell Harman, MD

Room: St. John's 24/25
CME Code: 9365

 

S33: Update on the Evaluation and Treatment of Paget’s Disease
Moderator: Gary W. Edelson, MD
Speaker: Henry G. Bone III, MD

Room: Suwannee 11/12
CME Code: 1235

 

S43: Challenging Pituitary Cases
Moderator: Alex Tessnow, MD
Speaker: Eliza Geer, MD

Room: Suwannee 16/17
CME Code: 7716

 

S53: Osteoporosis - Drug Holidays: Why, When and What's After
Moderator: Paul V.Tomasic, MD
Speaker: Paul D. Miller, MD

Room: St. John's 28/29
CME Code: 6711

 

S63: Emerging Therapies for Treatment of Hypoparathyroidism
Moderator: Donald A. Bergman, MD
Speaker: Bart L. Clarke, MD

Room: Suwannee 20/21
CME Code: 9542

 

S73: Medicine After the Holocaust
Moderator: Richard S. Rosenthal, MD
Speaker: Sheldon Rubenfeld, MD

Room: Suwannee 13/14
CME Code: 9817

 

S83: Approach to the Transgender Adolescent: A Case Study of the Jennings Family
Moderator: Stephen M. Rosenthal, MD
Case Study: The Jennings Family (“I am Jazz”)

Room: Suwannee 18/19
CME Code: 9648

6:30pm

ACE Convocation

7:30pm

President’s Gala

SUNDAY, MAY 29

7:00 am – 11:00 am

Registration

7:00 am - 8:00 am

Attendee Breakfast
Room: Panzacola F/G

7:30 am – 12:00 pm

CME Station Hours

8:00 am – 8:15 am

General Session Announcements

8:15 am – 8:45 am

SGS8: Controversies in the Approach to Adrenal Nodules
Moderator: Antonia E. Stephen, MD
Panel: Karel Pacak, MD, Antonia E. Stephen, MD; Peter M. Sadow, MD

Room: Panzacola F/G
CME Code: 7017

8:45 am – 9:30 am

SGS9: The Mystery of the Hidden Parathyroid Adenoma
Moderator: Jennifer L. Marti, MD
Panel: Azeez Farooki, MD; Peter M. Sadow, MD

Room: Panzacola F/G
CME Code: 5418

9:30 am – 9:45 am

Coffee Break

9:45 am – 11:00 am

SGS7: Dilemmas in Thyroid Cancer: Endocrine/Surgical Consensus
Moderator: Gregory W. Randolph, MD
Speaker: Peter A. Singer, MD, Gregory W. Randolph, MD; Peter M. Sadow, MD

Room: Panzacola F/G
CME Code: 1043

11:00 am – 11:15 am

Final Announcements; Adjournment

Declaration of Disclosure and Conflicts of Interest

It is the policy of AACE to ensure balance, independence, objectivity, and scientific rigor in all of its CME activities. Presentation content may include discussion of an unlabeled use of a commercial product or an investigational use of a product not yet approved for any purpose. AACE requires that participating faculty disclose to the audience any product(s) and its use(s) discussed in the educational activity that are unapproved/unlabeled for the use by the FDA or still considered investigational in nature.

Everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships. “Relevant financial relationships” are financial relationships in any amount occurring within the past 12 months that create a conflict of interest. AACE requires speakers, faculty, CME Committee, and other individuals who are in a position to control the content of this educational activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly evaluated by AACE for fair balance, scientific objectivity of studies mentioned in the presentation, and educational materials used as basis for content, and appropriateness of patient care recommendations.

The intent of this disclosure is not to prevent a speaker with commercial affiliations from presenting, but rather to provide learners with information from which they may make their own judgments. Informed learners are the final safeguards in assuring that a CME activity is independent from commercial influence.

AACE has reviewed all disclosures and resolved or managed all identified conflicts of interest for this educational activity, as applicable.

CME Accreditation Committee Disclosures

Dr. Richardo Correa reports that he does not have any relevant financial relationships with any commercial interests.

Dr. Stephen R. Crespin reports that he does not have any relevant financial relationships with any commercial interests.

Dr. Heather M. Huribal reports that she does not have any relevant financial relationships with any commercial interests.

Dr. Virginia A. LiVolsi reports that she has received pathology honoraria from Veracyte, Inc.

Dr. Dorothy S. Martinez reports that she does not have any relevant financial relationships with any commercial interests.

Dr. Fernando Ovalle reports that he has received consultant honoraria as well as a research grant for his role as investigator from AstraZeneca, Biodel, Inc., Boehringer Ingleheim GmbH, Eli Lilly & Co., GlaxoSmithKline, Janssen Pharmaceuticals, Inc., Medtronic, Inc., Novo Nordisk A/S and sanofi-aventis US LLC; and a research grant for his role as investigator from GI Dynamics, Inc., Merck & Co., Inc. and Pfizer,Inc.

Dr. Philip Raskin reports that he has received research support for the University of Texas Southwestern Medical Center from Amylin Pharmaceuticals LLC, Andromeda Biotech Ltd., AstraZeneca, Boehringer Ingelheim GmbH, Eli Lilly & Co., Intarcia Therapeutics, Inc., Merck & Co. Inc., Novo Nordisk A/S and Pfizer, Inc.; and advisor fees from Boston Therapeutics, Inc., GlaxoSmithkline and Janssen Pharmaceuticals, Inc.

Dr. Joseph M. Tibaldi reports that he has received speaker honoraria from AstraZeneca and Merck & Co., Inc.; and speaker/consultant honoraria from Novo Nordisk A/S.

Dr. Jeff Unger reports that he has received speaker honoraria from Janssen Pharmaceuticals, Inc. and Novo Nordisk A/S.

Program Committee Disclosures

*Dr. Jonathan Leffert reports that he has received speaker honoraria from Abbott and research grants for his role as investigator from Abbvie, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novo Nordisk A/S and sanofi-aventis US LLC. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Leffert has no identified conflicts of interest.

*Dr. Felice Caldarella reports that he has received speaker honoraria from Novo Nordisk A/S and Takeda Pharmaceutical U.S.A., Inc. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Caldarella has no identified conflicts of interest.

*Dr. Rachel Pessah-Pollack reports that she has received speaker honoraria from Boehringer Ingelheim GmbH. She also reports that her presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Pessah-Pollack has no identified conflicts of interest.

*Dr. S. Sethu Reddy reports that he has received advisor honoraria from Calibra Bioceuticals India Pvt. Ltd and speaker/advisor honoraria from Merck & Co., Inc. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Reddy has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

*Dr. Alan Garber reports that he has received member honoraria and advisory board consulting fees from Janssen Pharmaceuticals, Inc., Merck & Co., Inc. and Novo Nordisk A/S. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Garber has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

*Dr. George Grunberger reports that he has received speaker honoraria and research support for his role as investigator from AstraZeneca, Novo Nordisk A/S and Merck & Co.; speaker honoraria from Janssen Pharmaceuticals, Inc., Salix Pharmaceuticals, Inc. and sanofi-aventis US LLC. and research support for his role as investigator from Eli Lilly and Company. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Grunberger has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

*Dr. R. Mack Harrell reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Harrell has no identified conflicts of interest.

*Dr. A. Jay Cohen reports that he has received speaker honoraria from Abbvie, Inc., AstraZeneca and Boehringer Ingelheim GmbH; speaker/advisory board honoraria from Corcept Therapeutics and Endo Pharmaceuticals, Inc.; speaker/research trial honoraria from Janssen Pharmaceuticals, Inc. and speaker honoraria and research grants for trials from Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk A/S and sanofi-aventis US LLC. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Cohen has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

*Dr. M. Kathleen Figaro reports that she has received speaker honoraria from Novo Nordisk A/S. She also reports that her presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Figaro has no identified conflicts of interest.

*Dr. Jeffery Garber reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Garber has no identified conflicts of interest.

Dr. Martin Grajower reports that he has received speaker honoraria from Novo Nordisk A/S.

*Dr. Chris Guerin reports that he has received speaker honoraria from Novo Nordisk A/S. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Guerin has no identified conflicts of interest.

*Dr. Yehuda Handelsman reports that he has received consultant fees from Halozyme, Inc.; research grant support from Intarcia Therapeutics, Inc., Lexicon Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc.; research grant support and consultant fees from Amgen, Inc., Gilead, Merck & Co., Inc. and sanofi-aventis US LLC; consultant/speaker fees from Amarin Corporation, Amylin Pharmaceuticals LLC, Janssen Pharmaceuticals, Inc. and Vivus, Inc.; and research grant support and consultant/speaker fees from Boehringer Ingelheim GmbH, GlaxoSmithKline and Novo Nordisk A/S. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Handelsman has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

*Dr. Robert Henry reports that he has received scientific advisory board honoraria from AstraZeneca, Boehringer Ingelheim GmbH and Novo Nordisk A/S; research support from Hitachi, Ltd. and ViaCyte, Inc.; consultant honoraria from Alere and Ionis Pharmaceuticals, Inc.; and scientific advisory board honoraria and research grants for his role as consultant from Johnson & Johnson Services, Inc. /Janssen Pharmaceuticals, Inc. and sanofi-aventis US LLC. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Henry has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Edward Horton reports that he has received consultant honoraria from KnowledgePoint360 Group LLC, SAI MedPartners and Triangle Insights Group, LLC; advisory board honoraria from sanofi-aventis US LLC; data safety monitoring board honoraria from Theracos, Inc. and advisory board honoraria and travel from International Medical Press, PTS Diagnostics and Takeda Pharmaceutical U.S.A., Inc. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Horton has no identified conflicts of interest.

*Dr. Daniel Hurley reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Hurley has no identified conflicts of interest.

*Dr. Anne Leddy reports that she has received speaker fees from Eli Lilly and Company. She also reports that her presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Leddy has no identified conflicts of interest.

*Dr. David Charles Lieb reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Lieb has no identified conflicts of interest.

*Dr. William Reid Litchfield reports that he has received speaker honoraria from Novo Nordisk A/S. He also reports that his presentation(s) will no include discussion of any investigational or unlabeled use(s) of a product. Dr. Litchfield has no identified conflicts of interest.

*Dr. Mark Lupo reports that he has received speaker honoraria from Eisai Inc. and Interpace Diagnostics, LLC.; advisory honoraria from Rosetta Genomics; speaker/advisory honoraria from Genzyme Corporation, a Sanofi company; and speaker honoraria and research support from Veracyte, Inc. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Lupo has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

*Dr. Janet B. McGill reports that she has received advisor honoraria from Merck & Co., Inc.; advisor/speaker honoraria from Janssen Pharmaceuticals, Inc.; consultant/advisor honoraria from Boehringer Ingelheim GmbH; grant funding to WU for clinical trials from Dexcom, Inc., Intarcia Therapeutics, Inc., Novartis AG, Pfizer, Inc. and Lexicon Pharmaceuticals, Inc.; and advisor honoraria and grant funding to WU for clinical trials from Novo Nordisk A/S. She also reports that her presentation(s) will no include discussion of any investigational or unlabeled use(s) of a product. Dr. McGill has an identified conflict of interest and it has been resolved accordingly. She has been required by the AACE CME Accreditation Committee to base her presentation and recommendations on the best available, preferably published evidence/information.

*Dr. Mira Milas reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Milas has no identified conflicts of interest.

*Dr. Karel Pacak reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will include discussion of investigational or unlabeled use(s) of fluorodopamine, fluorodopa and 68GaDOTATATE for PET imaging. Dr. Pacak has no identified conflicts of interest.

*Dr. Sripriya Raman reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Raman has no identified conflicts of interest.

*Dr. Gregory Randolph reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Randolph has no identified conflicts of interest.

*Dr. Robert Rapaport reports that he has received global advisory board/advisory board honoraria from Novo Nordisk A/S and advisory board honoraria from Sandoz. He also reports that his presentation(s) will no include discussion of any investigational or unlabeled use(s) of a product. Dr. Rapaport has no identified conflicts of interest.

*Dr. Peter Singer reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Singer has no identified conflicts of interest.

*Dr. Lance Sloan reports that he has received speaker honoraria from AstraZeneca, Boehringer Ingelheim GmbH/Eli Lilly and Company, Hospira, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc. and Takeda Pharmaceutical U.S.A., Inc. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Sloan has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Carmen Solorzano reports that she does not have any relevant financial relationships with any commercial interests.

*Dr. Vin Tangpricha reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Tangpricha has no identified conflicts of interest.

Dr. Christine L. Twining reports that she does not have any relevant financial relationships with any commercial interests.

*Dr. Aaron Vinik reports that he has received research grants for his role as principal investigator from Daiichi Sankyo Company, Limited, Impeto Medical, Intarcia Therapeutics, Inc., Novo Nordisk A/S, Tercica, Inc., VeroScience LLC and ViroMed Laboratories Inc.; consultant fees from Ionis Pharmaceuticals, Inc.; consultant fees and a research grant for his role as principal investigator from Pfizer, Inc. and educational speaker honoraria and consultant fees from Merck & Co., Inc. and Nestle Health Science - Pamlab, Inc. He also reports that his presentation(s) will include discussion of investigational or unlabeled use(s) of alpha lipoic for somatic and autonomic neuropathy; topiramate for painful and small fiber neuropathy and methylcobolamin, methylfolate and pyridoxal phosphate for symptomatic neuropathy and patients on metformin with low B12 levels <450 pg. Dr. Vinik has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Nelson Watts reports that he has received stock option as a stockholder and royalties as co-founder/director from OsteoDynamics; consultant fees from Abbvie, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Radius Health, Inc. and sanofi-aventis US LLC; speaker honoraria and consultant from Amgen, inc. and speaker honoraria and research support through institution from Shire.

*Dr. Sandra Weber reports that she has received research grants for her role as principle investigator from National Institutes of Health, Novo Nordisk A/S and sanofi-aventis US LLC. She also reports that her presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Weber has no identified conflicts of interest.

Dr. Craig Wierum reports that he has received speaker honoraria from AstraZeneca, Novo Nordisk A/S and Eli Lilly and Company.

Dr. Susan Williams reports that she has received course speaker honoraria from Johnson & Johnson Services, Inc. and Shire.

*Dr. Farhad Zangeneh reports that he has received speaker honoraria from Arbor Pharmaceuticals, LLC., AstraZeneca, Eisai Co., Ltd, GlaxoSmithKline, Novo Nordisk A/S and Takeda Pharmaceutical U.S.A., Inc. and speaker/consultant honoraria from Boehringer Ingelheim GmbH/ Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Vivus, Inc. and Santarus, Inc./ Salix Pharmaceuticals, Inc. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Zangeneh has no identified conflicts of interest.

*designates a member of both faculty and program committee

Faculty Disclosures

Dr. Kenneth Ain reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Ain has no identified conflicts of interest.

Dr. Erik Alexander reports that he has received scientific advisory board honoraria from Asuragen, Inc. and consultant honoraria from Veracyte, Inc. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Alexander has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Myriam Allende-Vigo reports that she has received advisor honoraria from Merck & Co., Inc. and speaker honoraria from Abbott and Janssen Pharmaceuticals, Inc. She also reports that her presentation(s) will not include discussion of any investigational or unlabeled use(s) or a product. Dr. Allende-Vigo has an identified conflict of interest and it has been resolved accordingly. She has been required by the AACE CME Accreditation Committee to base her presentation and recommendations on the best available, preferably published evidence/information.

Dr. Richard Auchus reports that he has received contracted research support for his role as principal investigator from Strongbridge Biopharma plc; contracted research support for his role as investigator from Atterocor, Inc.; consultant fees from Corcept Therapeutics, bluebird bio, Inc., Ipsen Group, Janssen Pharmaceuticals, Inc.; advisory board fees from Laboratory Corporation of America Holdings; and consultant fees and contracted research support for his role as principal investigator from Novartis AG. He also reports that his presentation(s) will include discussion of investigational or unlabeled use(s) of abiraterone acetate, NBI-77860 and modified-release hydrocortisone for the treatment of congenital adrenal hyperplasia. Dr. Auchus has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Timothy Bailey reports that he has received research support from Abbott, ACON laboratories Inc., Alere, Animas Corporation, Cebix, Inc., Bristol-Myers Squibb Company, Dexcom, Inc., GlaxoSmithKline, Halozyme, Inc., Insulet Corporation, Lifescan, Inc., Eli Lilly and Company, Mannkind corp., Merck & Co., Orexigen Therapeutics, Inc., and Tandem Diabetes Care; consultant honoraria and research support from Bayer Healthcare AG, Becton Dickinson & Co, Medtronic, Inc., and sanofi-aventis US LLC.; and speaker/consultant honoraria and research support from Novo Nordisk A/S. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Bailey has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Zubair Baloch reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Baloch has no identified conflicts of interest.

Dr. Natan Bar-Chama reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Bar-Chama has no identified conflicts of interest.

Dr. David Bell reports that he has received speaker honoraria from AstraZeneca, Janssen Pharmaceuticals, Inc. and Novo Nordisk A/S and speaker/consultant honoraria from New Haven Pharmaceuticals. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Bell has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Regina Benjamin reports that she has received stock as a former director from Alere, Inc.; director honoraria from Ascension and Kaiser Permanente and speaker honoraria from American Program Bureau, Inc. She also reports that her presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Benjamin has no identified conflicts of interest.

Dr. Donald Bergman reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Bergman has no identified conflicts of interest.

Dr. William Biggs reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Biggs has no identified conflicts of interest.

Dr. Bruce Bode reports that he has received research support to his employer for his role as principal investigator from Abbott, Dexcom, Inc., Halozyme, Inc., and Mannkind Corporation; speaker honoraria from AstraZeneca, Eli Lilly and Company and Merck & Co., Inc.; research support for his role as principal investigator, speaker honoraria and advisory board consultant fees from Janssen Pharmaceuticals, Inc.; and research support to his employer for his role as principal investigator, consultant fees and speaker honoraria from Medtronic, Inc., Novo Nordisk A/S and sanofi-aventis US LLC. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Bode has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Henry Bone reports that he has received research funds for his role as investigator and consultant fees from Merck & Co. and Novartis AG. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Bone has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Lewis Braverman reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Braverman has no identified conflicts of interest.

Dr. Ronald Brazg reports that he has received research support for his role as investigator from Abbott, Bayer Healthcare AG, Medtronic, Inc. and F. Hoffmann-La Roche Ltd. He also reports that his presentation(s) will include discussion of investigational or unlabeled use(s) of pump for hybride closed loop system. Dr. Brazg has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Elise Brett reports that her spouse receives a salary as an employee from Novo Nordisk A/S. She also reports that her presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Brett has no identified conflicts of interest.

Dr. Maria Cabanillas reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation(s) will include discussion of investigational or unlabeled use(s) of dabrafenib for papillary thyroid carcinoma, and trametinib and selumetinib for differentiated thyroid cancer. Dr. Cabanillas has no identified conflicts of interest.

Dr. Pauline Camacho reports that she has received a research grant for her role as principal investigator from Eli Lilly and Company; advisory board fees from Intarcia Therapeutics, Inc; stock from Abbott/Abbvie, Inc.; and a research grant for her role as principal investigator and advisory board member fees from Amgen, Inc. She also reports that her presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Camacho has an identified conflict of interest and it has been resolved accordingly. She has been required by the AACE CME Accreditation Committee to base her presentation and recommendations on the best available, preferably published evidence/information.

Dr. Juan Brito Campana reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Campana has no identified conflicts of interest.

Dr. Nancy Carrasco reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Carrasco has no identified conflicts of interest.

Dr. Elena Christofides reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Christofides has no identified conflicts of interest.

Dr. Bart Clarke reports that he has received a research grant for his role as principal investigator from NPS pharmaceuticals, Inc. and member Demosumab Oncology DMC fee from Amgen, Inc. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Clarke has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Rhoda Cobin reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Cobin has no identified conflicts of interest.

Dr. Yank D. Coble reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Coble has no identified conflicts of interest.

Dr. Eli Coleman reports that he has received co-chair advisory committee honoraria from Church & Dwight., Inc. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Coleman has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Jaime Davidson reports that he has received advisory board fees from Amgen, Inc., Aspire Bariatrics and Merck & co., Inc.; speaker fees from Takeda Pharmaceutical U.S.A., Inc. and speaker/ advisory board fees from AstraZeneca, Eli Lilly and Company, Janssen Pharmaceuticals, Inc. and Novo Nordisk A/S. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Davidson has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Robert Eckel reports that he has received scientific advisory consulting fees from sanofi-aventis US LLC. and Regeneron Pharmaceuticals, Inc. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Eckel has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Gary Edelson reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Edelson has no identified conflicts of interest.

Dr. Daniel Einhorn reports that he has received consultant honoraria from Bristol-Myers Squibb Company/ AstraZeneca/ Amylin Pharmaceuticals LLC, Halozyme, Inc., Eli Lilly and Company and Novo Nordisk; research grant support from AstraZeneca, Mannkind Corporation, Pfizer, Inc., sanofi-aventis US LLC and Takeda Pharmaceutical U.S.A., Inc; stock options for his role as consultant from ADOCIA, Freedom Meditech and Glysens Incorporated; and a grant for research and consulting from Janssen Pharmaceuticals, Inc. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Einhorn has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Azeez Farooki reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Farooki has no identified conflicts of interest.

Dr. Sergio Fazio reports that he has received advisor/consultant fees from Aegerion Pharmaceuticals, Inc., BASF SE, Kowa Pharmaceuticals America, Inc., Merck & Co., Inc., New Haven Pharmaceuticals and sanofi-aventis US LLC. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Fazio has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Ilene Fennoy reports that she has received consultant fees from Novo Nordisk A/S. She also reports that her presentation(s) will include discussion of investigational or unlabeled use(s) of liraglutide, lorcaserin and phentermine/topiramate for weight loss. Dr. Fennoy has an identified conflict of interest and it has been resolved accordingly. She has been required by the AACE CME Accreditation Committee to base her presentation and recommendations on the best available, preferably published evidence/information.

Dr. Naomi Fisher reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Fisher has no identified conflicts of interest.

Dr. Maria Fleseriu reports that she has received research support to her institution for her role as principal investigator from Novartis AG. She also reports that her presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Fleseriu has an identified conflict of interest and it has been resolved accordingly. She has been required by the AACE CME Accreditation Committee to base her presentation and recommendations on the best available, preferably published evidence/information.

Dr. Vivian Fonseca reports that he has received research grant support to Tulane from Asahi, Bayer Healthcare AG, Eli Lilly and Company and Gilead. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Fonseca has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Douglas Fridsma reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Fridsma has no identified conflicts of interest.

Dr. Satish Garg reports that he has received advisory board consulting fees from Hoffman-La Roche Ltd.; research grants from MyDario USA, JDRF, National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases and T1D Exchange; and research grants and advisory board consulting fees from Eli Lilly and Company, Lexicon Pharmaceuticals, Inc., Medtronic, Inc., Merck & Co., Inc., Novo Nordisk A/S and sanofi-aventis US LLC. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Garg has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. W. Timothy Garvey reports that he has received contracted research for his role as principal investigator from Amylin Pharmaceuticals, LLC, AstraZeneca, Elcelyx Therapeutics, Inc., Lexicon Pharmaceuticals, Inc., sanofi-aventis US LLC. and Weight Watchers International, Inc.; consultant fees from Boehringer Ingelheim GmbH, Daiichi Sankyo Company, Limited., Janssen Pharmaceuticals, Inc., Liposcience, Inc., Takeda Pharmaceutical U.S.A., Inc. and Vivus, Inc.; is a stockholder of Bristol-Myers Squibb Company, Ionis Pharmaceuticals, Inc., Eli Lilly and Company and Novartis AG; consultant fees and contracted research for his role as principal investigator from Eisai, Inc. and Novo Nordisk A/S; and stocks as a stockholder and contracted research for his role as principal investigator from Merck & Co., Inc. and Pfizer, Inc. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Garvey has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Eliza Geer reports that she has received consultant honoraria from Chiasma, Cortendo, Ipsen Group and Pfizer, Inc.; speaker honoraria from Regeneron Pharmaceuticals, Inc.; and consultant honoraria and a research grant for his role as principal investigator from Novartis AG. She also reports that her presentation(s) will include discussion of investigational or unlabeled use(s) of LCI699 and levoketoconazole for the treatment of Cushing’s and oral octreotide for the treatment of acromegaly. Dr. Geer has an identified conflict of interest and it has been resolved accordingly. She has been required by the AACE CME Accreditation Committee to base her presentation and recommendations on the best available, preferably published evidence/information.

Dr. Hossein Gharib reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Gharib has no identified conflict of interest.

Dr. J. Michael Gonzalez-Campoy reports that he has received a research fund from Boehringer Ingelheim GmbH; speaker honoraria from GlaxoSmithKline, Janssen Pharmaceuticals, Inc., Takeda Pharmaceutical U.S.A., Inc. and Vivus, Inc.; consultant honoraria from Valentx, Inc.; speaker honoraria and research funds from AstraZeneca and Eisai Inc. and consultant/speaker honoraria from Novo Nordisk A/S. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Gonzalez-Campoy has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Ved Gossain reports that he has received a speaker fee from Novo Nordisk A/S. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Gossain has no identified conflict of interest.

Dr. Fernando Guerrero-Romero reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will no include discussion of any investigational or unlabeled use(s) of a product. Dr. Guerrero-Romero has no identified conflicts of interest.

Dr. Richard Haas reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Haas has no identified conflict of interest.

Dr. Osama Hamdy reports that he has received clinical research support and advisory board honoraria from Metagenics Inc.; consultant honoraria from Merck & Co., Inc. and advisory board honoraria from AstraZeneca and Novo Nordisk A/S. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Hamdy has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Sherman Mitchell Harman reports that he does not have any relevant financial relationships with any commercial interests. He reports that his presentation(s) will include discussion of investigational or unlabeled use(s) of premarin (conjugated estrogen) and climara (transdermal estrogen) for the prevention of coronary disease. Dr. Harman has no identified conflict of interest.

Dr. Israel Hartman reports that he has received speaker fees from AstraZeneca, GlaxoSmithKline, Eli Lilly and Company and sanofi-aventis US LLC and speaker honoraria from Novo Nordisk A/S. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Hartman has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Ian Hay reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Hay has no identified conflicts of interest.

Dr. Wyle Hembree reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Hembree has no identified conflicts of interest.

Dr. James Hennessey reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Hennessey has no identified conflicts of interest.

Dr. Tara Henrichsen reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Henrichsen has no identified conflicts of interest.

Dr. Irl Hirsch reports that he has received consultant honoraria from Abbott, Becton Dickinson & Co and F. Hoffmann-La Roche Ltd. and a research grant for his role as principal investigator from Novo Nordisk A/S. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Hirsch has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Alan Ho reports that he has received research funding for his role as principal investigator of a trial from AstraZeneca; research funding for his role as principal investigator of trials from Bayer Healthcare AG, Kolltan Pharmaceuticals, Inc. and Kura Oncology, Inc.; research funding for his role as investigator of a trial from Eli Lilly and Company; advisory board honoraria from Novartis AG; and advisory board honoraria and research funding for his role as investigator of a trial from Eisai Inc. He reports that his presentation(s) will include discussion of investigational or unlabeled use(s) of vemurafenib, KTN3379 and trametinib for the treatment of thyroid cancer. Dr. Ho has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Michael Holick reports that he has received consultant fee from Quest Diagnostics Incorporated. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Holick has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Jay Horton reports that he has received consultant fees from Aegerion Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals, Inc. and sanofi-aventis US LLC and advisory board stock options from Catabasis Pharmaceuticals, Inc. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Horton has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. James Howe reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will no include discussion of any investigational or unlabeled use(s) of a product. Dr. Howe has no identified conflicts of interest.

Dr. Patrick Ryan Hungerford reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will no include discussion of any investigational or unlabeled use(s) of a product. Dr. Hungerford has no identified conflicts of interest.

Dr. Jonathan Insel reports that he has received stock as a stockholder from Abbott, ACADIA Pharmaceuticals Inc., Allergan, Inc., Amgen, Inc., Bristol-Myers Squibb Company, Dexcom, Inc., Gilead Sciences, Inc., Johnson & Johnson Services, Inc., Kite Pharma, Eli Lilly and Company, Pfizer, Inc., Radiant Pharmaceuticals Ltd. and Trevena, Inc. He also reports that his presentation(s) will no include discussion of any investigational or unlabeled use(s) of a product. Dr. Insel has no identified conflicts of interest.

Dr. Scott Isaacs reports that he has received speaker honoraria from Abbvie, Inc. and Takeda Pharmaceutical U.S.A., Inc. and speaker/consultant honoraria from Novo Nordisk A/S. He reports that his presentation(s) will include discussion of investigational or unlabeled use(s) of bupropion, metformin and topiramate for weight loss. Dr. Isaacs has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Ania Jastreboff reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation(s) will no include discussion of any investigational or unlabeled use(s) of a product. Dr. Jastreboff has no identified conflicts of interest.

Dr. Lois Jovanovic reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation(s) will no include discussion of any investigational or unlabeled use(s) of a product. Dr. Jovanovic has no identified conflicts of interest.

Dr. Sathya Jyothinagaram reports that he has received speaker honoraria from Merck & Co., Inc. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Jyothinagaram has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Matthew Kulke reports that he has received consultant fees from Ipsen Group, Novartis AG and Lexicon Pharmaceuticals, Inc. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Kulke has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Howard Lando reports that he has received speaker honoraria from Abbvie, Inc., AstraZeneca, Merck Sharp & Dohm and Janssen Pharmaceuticals, Inc. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product.
Dr. Lando has no identified conflicts of interest.

Dr. Edward Laws reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Laws has no identified conflicts of interest.

Dr. Stephanie Lee reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Lee has no identified conflicts of interest.

Dr. Derek LeRoith reports that he has received consultant honoraria from AstraZeneca, Bristol-Myers Squibb Company/AstraZeneca, Janssen Pharmaceuticals, Inc. and sanofi-aventis US LLC. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. LeRoith has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Alice Levine reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Levine has no identified conflicts of interest.

Dr. Philip Levy reports that he has received speaker honoraria from AstraZeneca, Boehringer Ingelheim GmbH, Janssen Pharmaceuticals, Inc. and Novo Nordisk A/S. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Levy has no identified conflicts of interest.

Dr. Angelo Licata reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Licata has no identified conflicts of interest.

Dr. Miguel Madero reports that he has received speaker honoraria from AstraZeneca, Boehringer Ingelheim GmbH, MSD pharmaceutical, Janssen Pharmaceuticals, Inc. and sanofi-aventis US LLC. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Madero has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Jennifer Marti reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Marti has no identified conflicts of interest.

Dr. Alvin Matsumoto reports that he has received consultant fees from Endo Pharmaceuticals Inc., Eli Lilly and Company and United States Anti-Doping Agency; royalty for his role as editor from UpToDate, Inc.; research support for his role as investigator from GlaxoSmithKline; and research support for his role as investigator and consultant fees from Abbvie, Inc. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Matsumoto has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Michael McClung reports that he has received consultant fees and speaker honoraria from Amgen, Inc. and Merck & Co., Inc. He also reports that his presentation(s) will include discussion of investigational or unlabeled use(s) of odanacatib and anti-sclerostin antibodies for possible treatment of osteoporosis. Dr. McClung has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Michael McDermott reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. McDermott has no identified conflicts of interest.

Dr. Darren McGuire reports that he has received consultant honoraria from Regeneron Pharmaceuticals, Inc. and sanofi-aventis USLLC; trial leadership honoraria from Eisai, Inc., Eli Lilly and Company, GlaxoSmithKline, Lexicon Pharmaceuticals, Inc. and Takeda Pharmaceutical U.S.A., Inc. and trial leadership/consultant honoraria from AstraZeneca, Boehringer Ingelheim GmbH, Janssen Pharmaceuticals, Inc., Merck & Co., Inc. and Novo Nordisk A/S. He also reports that his presentation(s) will include discussion of investigational or unlabeled use(s) of diabetes drugs for cardiovascular effects. Dr. McGuire has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Jeffrey Mechanick reports that he has received lecture and program development honoraria from Abbott. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Mechanick has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Shlomo Melmed reports that he has received consultant fees from Novartis AG. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Melmed has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Mosies Mercado reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Mercado has no identified conflicts of interest.

Dr. Deborah Merke reports that she has received research funding for her role as principal investigator of clinical trial from Diurnal limited. She also reports that her presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Merke has an identified conflict of interest and it has been resolved accordingly. She has been required by the AACE CME Accreditation Committee to base her presentation and recommendations on the best available, preferably published evidence/information.

Dr. Paul Miller reports that he has received research grant support from Regeneron Pharmaceuticals, Inc.; research grant support and honoraria from National Bone Health Alliance; speaker/consultant honoraria and research grant support from Alexion Pharmaceuticals; advisory board/consultant honoraria and research grant support from Amgen, Inc., Eli Lilly and Company and Merck & Co., Inc. and consultant honoraria from Radius Health, Inc., Novo Nordisk A/S and Takeda Pharmaceutical U.S.A., Inc. He also reports that his presentation(s) will include discussion of investigational or unlabeled use(s) of anti sclerostin antibody and cathepsin k inhibitors for osteoporosis. Dr. Miller has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Etie Moghissi reports that she has received consultant/speaker fees from AstraZeneca, Eli Lilly and Company, Merck & Co., Inc. and Novo Nordisk A/S and speaker fees from Boehringer Ingelheim GmbH, Janssen Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. She also reports that her presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Moghissi has an identified conflict of interest and it has been resolved accordingly. She has been required by the AACE CME Accreditation Committee to base her presentation and recommendations on the best available, preferably published evidence/information.

Dr. Sri Prakash Mokshagundam reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will no include discussion of any investigational or unlabeled use(s) of a product. Dr. Mokshagundam has no identified conflicts of interest.

Dr. Stanley Monstrey reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will no include discussion of any investigational or unlabeled use(s) of a product. Dr. Monstrey has no identified conflicts of interest.

Mr. John Morley reports that he has received consultant fees from Astellas Pharma US, Inc., Akros Pharma Inc., Boehringer Ingelheim GmbH, Merck & Co., Inc. and sanofi-aventis US LLC; grant research support from Nestle Health Science and Kemin Industries, Inc., U.S.A and consultant/speaker fees from Nutricia. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Morley has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Karl Nadolsky reports that he is a stockholder of Arena Pharmaceuticals, Inc., Orexigen Therapeutics, Inc. and Vivus, Inc. and receives ownership for his role as investment/development from The Leaner Living Store. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Nadolsky has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Christopher Newgard reports that he has received consultant honoraria from Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Medimmune, Merck & Co., Inc. and Pfizer, Inc. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Newgard has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Yuri Nikiforov reports that he has received consultant fees from Quest Diagnostics Incorporated. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Nikiforov has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Steven Nissen reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will include discussion of investigational or unlabeled use(s) of SGLT2 inhibition for DM treatment. Dr. Nissen has no identified conflicts of interest.

Ms. Sondra O’Callaghan reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Ms. O’Callaghan has no identified conflicts of interest.

Dr. Thomas O’Dorisio reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. O’Dorisio has no identified conflicts of interest.

Dr. Darius Paduch reports that he has received speaker honoraria from Abbvie, Inc. and research grant support for his role as investigator from Eli Lilly and Company. He also reports that his presentation(s) will include discussion of investigational or unlabeled use(s) of clomiphene citrate and anastrozole for reversal of pituitary suppression. Dr. Paduch has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Anthony Parker reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Parker has no identified conflicts of interest.

Dr. Steven Petak reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Petak has no identified conflicts of interest.

Dr. Richard Pratley reports that he has received consultant fees from Boehringer Ingelheim GmbH, Glaxo Smith & Kline, Hanmi Pharm.Co.,Ltd., Janssen Pharmaceuticals, Inc. and Ligand Pharmaceutical, Inc.; a research grant from sanofi-aventis US LLC; speaker/consultant fee from AstraZeneca; research grant support and consultant fees from Eli Lilly and Company, Merck & Co., Inc. and Takeda Pharmaceutical U.S.A., Inc. and research grant support and speaker/consultant honoraria from Novo Nordisk A/S. All services rendered by Dr. Pratley are paid directly to Florida Hospital, a non-profit organization. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Pratley has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Martin Prazny reports that he has received speaker/trainer/educator honoraria from Medtronic, Inc. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Prazny has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Ms. Jill Rathbun reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Ms. Rathbun has no identified conflicts of interest.

Dr. Robert Ratner reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Ratner has no identified conflicts of interest.

Dr. Kate Roberts reports that she has received speaker honoraria from Janssen Pharmaceuticals, Inc. She also reports that her presentation(s) will no include discussion of any investigational or unlabeled use(s) of a product. Dr. Roberts has no identified conflicts of interest.

Dr. Victor Roberts reports that he has received speaker honoraria from Novo Nordisk A/S; consultant honoraria from AHM, Boehringer Ingelheim GmbH, Decile Ten, Medical Exchange International and Medtronic, Inc. and survey consultant fee from Schlesinger Associates. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Roberts has no identified conflicts of interest.

Dr. Richard Rosenthal reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Rosenthal has no identified conflicts of interest.

Dr. Stephen Rosenthal reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will include discussion of investigational or unlabeled use(s) of leuprolide and histrellin for GnRH agonist/pubertal blocker.
Dr. Rosenthal has no identified conflicts of interest.

Dr. Daniel Ruan reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Ruan has no identified conflicts of interest.

Dr. Sheldon Rubenfeld reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Rubenfeld has no identified conflicts of interest.

Dr. Peter Sadow reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Sadow has no identified conflicts of interest.

Dr. Julie Sosa reports that she has received consultant fees as member of the data Monitoring committee for the Medullary Thyroid Cancer registry funded by UBC from AstraZeneca, GlaxoSmithKline, Eli Lilly and Company and Novo Nordisk A/S. She also reports that her presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Sosa has an identified conflict of interest and it has been resolved accordingly. She has been required by the AACE CME Accreditation Committee to base her presentation and recommendations on the best available, preferably published evidence/information.

Dr. Antonia Stephen reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Stephen has no identified conflicts of interest.

Dr. Pam Taub reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Taub has no identified conflicts of interest.

Dr. Alex Tessnow reports that he has received a research grant for his role as principle investigator from Akrimax Pharmaceuticals, LLC. and consultant fees from Genzyme Corporation, a Sanofi company. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Tessnow has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Holly Thacker reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Thacker has no identified conflicts of interest.

Dr. Paul Tomasic reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Tomasic has no identified conflicts of interest.

Dr. Gary Trager reports that he has received speaker/consultant honoraria from Abbvie, Inc., Amarin Corp, AstraZeneca and Bristol-Myers Squibb Company; and speaker/consultant honoraria and a grant for his role as a trial principal investigator from Takeda Pharmaceutical U.S.A., Inc. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Trager has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Dace Trence reports that she is a stockholder of Medtronic, Inc. and sanofi-aventis U.S. LLC. She also reports that her presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Trence has no identified conflicts of interest.

Dr. Guillermo Umpierrez reports that he has received research grant support for his role as investigator for initiated research and advisory/consultant honoraria from Boehringer Ingelheim GmbH and Merck & Co., Inc.; research grant support for his role as investigator for initiated research from AstraZeneca and Novo Nordisk A/S and Advisory/consultant honoraria from Johnson & Johnson Services, Inc. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Umpierrez has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Douglas Van Nostrand reports that he has received speaker honoraria from Genzyme Corporation, a Sanofi company and consultant honoraria from Jubilant DraxImage Inc. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Van Nostrand has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Joseph Verbalis reports that he has received consultant fees from Ferring Pharmaceuticals and Otsuka America Pharmaceutical, Inc. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Verbalis has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Gregory Wiseman reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Wiseman has no identified conflicts of interest.

Dr. Kathleen Wyne reports that she has received advisory board honoraria from Akcea Therapeutics. She also reports that her presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Wyne has no identified conflicts of interest.

Dr. William Young reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Young has no identified conflicts of interest.

Dr. William Zigrang reports that he has received speaker/training honoraria from AstraZeneca and Bristol-Myers Squibb Company and contracted research reimbursement from Eli Lilly and Company. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Zigrang has no identified conflicts of interest.

 

Oral Presentation Faculty Disclosures

Dr. Saleh Aldasouqi reports that he has received speaker fees from Janssen Pharmaceuticals, Inc. and sanofi-aventis US LLC. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Aldasouqi has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Juan Frias reports that he has received research grants for his role as investigator from Abbvie, Inc., Amgen, Inc., Bristol-Myers Squibb Company, Elcelyx Therapeutics, Inc., Eli Lilly and Company, Gilead Sciences, Inc., Ionis Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk A/S and Pfizer, Inc.; and research grants for his role as investigator and independent contractor honoraria from AstraZeneca, Johnson & Johnson Services, Inc., Proteus Digital Health and sanofi-aventis US LLC. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Frias has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Ms. Nesreen Hagahmed reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Ms. Hagahmed has no identified conflicts of interest.

Dr. Lima Lawrence reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Lawrence has no identified conflicts of interest.

Dr. David Charles Lieb reports that he does not have any relevant financial relationships with any commercial interests. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Lieb has no identified conflicts of interest.

Dr. Mark Lupo reports that he has received speaker honoraria from Eisai Inc. and Interpace Diagnostics, LLC.; advisory honoraria from Rosetta Genomics; speaker/advisory honoraria from Genzyme Corporation, a Sanofi company; and speaker honoraria and research support from Veracyte, Inc. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Lupo has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. S. Sethu Reddy reports that he has received advisor honoraria from Calibra Bioceuticals India Pvt. Ltd and speaker/advisor honoraria from Merck & Co., Inc. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Reddy has an identified conflict of interest and it has been resolved accordingly. He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Leo Seman reports that he receives a full salary for his role as medical director from Boehringer Ingleheim GmbH. He also reports that his presentation(s) will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Seman has no identified conflicts of interest.